Search

Your search keyword '"Rodriguez-Antolin A"' showing total 60 results
Start Over Author "Rodriguez-Antolin A" Publisher elsevier b.v.
60 results on '"Rodriguez-Antolin A"'

1. Molecular diagnosis of cystic fibrosis by RNA obtained from nasal epithelial cells

Author

Prior-de Castro, Carmen, Martínez Gallego, Miguel Ángel, Gómez-González, Clara, de Sancho Martín, Rubén, Rodríguez-Antolín, Carlos, Rodríguez-Jiménez, Carmen, del Pozo Mate, Ángela, Zamarrón de Lucas, Ester, Ruiz de Valbuena Maiz, Marta, de Manuel Gómez, Cristina, Alcolea Batres, Sergio, Prados Sánchez, María Concepción, and J Torres, Rosa

Published
2024
Full Text
View/download PDF

2. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Author

Matsubara, Nobuaki, Chi, Kim N., Özgüroğlu, Mustafa, Rodriguez-Antolin, Alfredo, Feyerabend, Susan, Fein, Luis, Alekseev, Boris Y., Sulur, Giri, Protheroe, Andrew, Li, Susan, Mundle, Suneel, De Porre, Peter, Tran, Namphuong, and Fizazi, Karim

Published
2020
Full Text
View/download PDF

13. A1061 - Comparative study between cognitive fusion targeted prostate biopsy technique and software-based magnetic resonance imaging-ultrasonography image-fusion targeted prostate biopsy technique in a high-volume hospital

Author

Calzas Montalvo, C., Sopena Sutil, R., Juste Álvarez, S., Gil Moradillo, J., Garcia Gonzalez, L., Rodriguez-Izquierdo Jimenez, M., García Gómez, B., Duarte Ojeda, J.M., Caro González, M.A.D.P., De la Calle Moreno, A., Gonzalez Ginel, I., García-Rayo Encinas, C., and Rodriguez Antolín, A.

Published
2024
Full Text
View/download PDF

14. A0731 - First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients

Author

Guerrero-Ramos, F., De Velasco, G., Duenas, M., Paramio, J., García, V.M., Gómez-Canizo, C., Rodríguez-Izquierdo, M., Hernández-Arroyo, M., Martín-Torres, M.P., Álvarez-Rodríguez, P., Suárez, C., Morales, L., Ponce, S., Rodríguez-Antolín, A., and Castellano, D.

Published
2024
Full Text
View/download PDF

24. A1105 - Transplant renal artery stenosis: Study of incidence using doppler ultrasound, risk factors and analysis effect in graft outcomes

Author

Calzas Montalvo, C., Medina Polo, J., Miranda Utrera, N.R., Caro González, M.P., Santos Perez De La Blanca, R., Hernandez Arroyo, M., Peña Vallejo, E., Teigell Tobar, J., Juste Álvarez, S., De La Calle Moreno, A., Rodriguez Antolín, A., Duarte Ojeda, J.M., Pamplona Casamayor, M., Tejido Sánchez, Á., García González, L., Arrébola Pajares, A., and Rodriguez De La Calle, J.

Published
2022
Full Text
View/download PDF

27. P0121 - Urological surgery remained safe during the second wave of SARS-CoV-2 pandemic in a high incidence area

Author

González Díaz, A., Santos-Pérez De La Blanca, R., Gil-Moradillo, J., Calzas-Montalvo, C., Caro-González, M.D.P., Juste-Álvarez, S., De La Calle-Moreno, A., Abad-López, P., Peña-Vallejo, E., Miranda-Utrera, N.R., Rosillo-Ramírez, N., Brandini-Romersi, A.M., Varela-Rodríguez, C., Rodríguez-Antolín, A., and Tejido-Sánchez, Á.

Published
2021
Full Text
View/download PDF

30. MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species.

Author

Vera-Puente, Olga, Rodriguez-Antolin, Carlos, Salgado-Figueroa, Ana, Michalska, Patrycja, Pernia, Olga, Reid, Brett M., Rosas, RocÍo, Garcia-Guede, Alvaro, SacristÁn, Silvia, Jimenez, Julia, Esteban-Rodriguez, Isabel, Martin, M. Elena, Sellers, Thomas A., León, Rafael, Gonzalez, VÍctor M., De Castro, Javier, and Ibanez de Caceres, Inmaculada

Abstract

Adjuvant chemotherapy for solid tumors based on platinum-derived compounds such as cisplatin is the treatment of choice in most cases. Cisplatin triggers signaling pathways that lead to cell death, but it also induces changes in tumor cells that modify the therapeutic response, thereby leading to cisplatin resistance. We have recently reported that microRNA-7 is silenced by DNA methylation and is involved in the resistance to platinum in cancer cells through the action of the musculoaponeurotic fibrosarcoma oncogene family, protein G (MAFG). In the present study, we first confirm the miR-7 epigenetic regulation of MAFG in 44 normal- and/or tumor-paired samples in non-small-cell lung cancer (NSCLC). We also provide translational evidence of the role of MAFG and the clinical outcome in NSCLC by the interrogation of two extensive in silico databases of 2019 patients. Moreover, we propose that MAFG-mediated resistance could be conferred due to lower reactive oxygen species production after cisplatin exposure. We developed specifically selected aptamers against MAFG, with high sensitivity to detect the protein at a nuclear level probed by aptacytochemistry and histochemistry analyses. The inhibition of MAFG activity through the action of the specific aptamer apMAFG6F increased the levels of reactive oxygen species production and the sensitivity to cisplatin. We report first the specific nuclear identification of MAFG as a novel detection method for diagnosis in NSCLC, and then we report that MAFG modulates the redox response and confers cell protection against free radicals generated after platinum administration, thus also being a promising therapeutic target. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

34. 1013 - Kidney transplantation from uncontrolled donation after circulatory death (IIa): Organ procurement and renal harvested over a ten year period

Author

Medina Polo, J., Justo-Quintas, J., Gil-Moradillo, J., De La Rosa-Kehrmann, F., Pamplona-Casamayor, M., Rodríguez-Antolín, A., Duarte-Ojeda, J.M., Tejido-Sánchez, A., Villacampa-Aubá, F., Sopeña-Sutil, R., Benitez-Sala, R., Guerrero-Ramos, F., Andrés-Belmonte, A., and Passas-Martínez, J.B.

Published
2017
Full Text
View/download PDF

46. The impact of next-generation sequencing on the DNA methylation-based translational cancer research.

Author

Soto, Javier, Rodriguez-Antolin, Carlos, Vallespín, Elena, de Castro Carpeño, Javier, and Ibanez de Caceres, Inmaculada

Abstract

Epigenetics is currently in an exponential phase of growth, constituting one of the most promising fields in science, particularly in cancer research. Impaired epigenetic processes can lead to abnormal gene activity or inactivity, causing cellular disorders that are closely associated with tumor initiation and progression. Thus, there is a pivotal role of massive sequencing techniques for epigenetics, which aim to find novel biomarkers, factors of prognosis and prediction, and targets for achieving personalized treatments. We present a brief description of the evolution of next-generation sequencing technologies and its coupling with DNA methylation analysis techniques, highlighting its future in translational medicine and presenting significant findings in several malignancies. We also expose critical topics related to the implementation of these approaches, which is expected to be affordable for most research centers in the near future. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Author

Fizazi, Karim, Tran, NamPhuong, Fein, Luis, Matsubara, Nobuaki, Rodriguez-Antolin, Alfredo, Alekseev, Boris Y, Özgüroğlu, Mustafa, Ye, Dingwei, Feyerabend, Susan, Protheroe, Andrew, Sulur, Giri, Luna, Yesenia, Li, Susan, Mundle, Suneel, and Chi, Kim N

Subjects
*CASTRATION-resistant prostate cancer, *ABIRATERONE acetate, *PROSTATE cancer, *SURVIVAL analysis (Biometry), *PREDNISONE, *PROGRESSION-free survival
Abstract

Background: In the interim analyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement in overall survival and radiographic progression-free survival compared with placebos plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (mCSPC). Here, we present long-term survival outcomes and safety of abiraterone acetate plus prednisone and ADT from the final analysis of the LATITUDE study.Methods: This is a multicentre, randomised, double-blind, phase 3 trial done at 235 sites in 34 countries. Eligible patients (men aged ≥18 years) had newly diagnosed, histologically or cytologically confirmed prostate cancer with metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and at least two of the three high-risk prognostic factors (Gleason score of ≥8, presence of three or more lesions on bone scan, or presence of measurable visceral metastasis except lymph node metastasis). Patients were randomly assigned (1:1) to receive abiraterone acetate (1000 mg) once daily orally plus prednisone (5 mg) once daily orally and ADT (abiraterone acetate plus prednisone group) or matching placebos plus ADT (placebo group); each treatment cycle was 28 days. Randomisation was done by a centralised interactive web response system in a country-by-country scheme using permuted block randomisation, stratified by presence of visceral disease and ECOG performance status. The coprimary endpoint of overall survival was assessed in the intention-to-treat population. This study is registered at ClinicalTrials.gov, number NCT01715285 and is complete.Findings: Between Feb 12, 2013, and Dec 11, 2014, 1209 patients were screened, of whom ten were ineligible because of study site violations. 1199 patients were randomly assigned to either the abiraterone acetate plus prednisone group (n=597) or placebo group (n=602). After the results of the first interim analysis (cutoff date Oct 31, 2016), the study was unmasked to patients and investigators, and patients in the placebo group were allowed to cross over to receive abiraterone acetate and prednisone plus ADT treatment as per a protocol amendment (Feb 15, 2017) in an open-label extension phase of the study (up to 18 months from the protocol amendment). This final analysis (data cutoff Aug 15, 2018) was done after a median follow-up of 51·8 months (IQR 47·2-57·0) and 618 deaths (275 [46%] of 597 in the abiraterone acetate plus prednisone group and 343 [57%] of 602 in the placebo group). Overall survival was significantly longer in the abiraterone acetate plus prednisone group (median 53·3 months [95% CI 48·2-not reached]) than in the placebo group (36·5 months [33·5-40·0]), with a hazard ratio of 0·66 (95% CI 0·56-0·78; p<0·0001). The most common grade 3-4 adverse events were hypertension (125 [21%] in the abiraterone acetate plus prednisone group vs 60 [10%] in the placebo group vs three [4%] in the 72 patients who crossed over from placebo to abiraterone acetate plus prednisone) and hypokalaemia (70 [12%] vs ten [2%] vs two [3%]). Serious adverse events of any grade occurred in 192 (32%) of 597 patients in the abiraterone acetate plus prednisone group, 151 (25%) of 602 in the placebo group, and four (6%) of 72 in the crossover group. The most common treatment-related serious adverse event was hypokalaemia (four [1%] patients in the abiraterone acetate plus prednisone group and none in the other groups). Treatment-related deaths occurred in three (<1%) patients each in the abiraterone acetate plus prednisone group (gastric ulcer perforation, sudden death, and cerebrovascular accident) and the placebo group (sudden death, cerebrovascular accident, and pneumonia), with none in the crossover group.Interpretation: The combination of abiraterone acetate plus prednisone with ADT was associated with significantly longer overall survival than placebos plus ADT in men with newly diagnosed high-risk mCSPC and had a manageable safety profile. These findings support the use of abiraterone acetate plus prednisone as a standard of care in patients with high-risk mCSPC.Funding: Janssen Research & Development. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results